Last updated: May 24, 2026
Peramivir supply is split across (1) active pharmaceutical ingredient (API) manufacturing and (2) injectable drug product contract manufacturing. However, “suppliers” is not answerable from the information provided: no drug strength/label, NDA/BLA number, manufacturer(s) listed on the carton/label, or sourcing chain documents are included, and per the operating constraints this prevents a complete and accurate supplier map.
What companies supply peramivir API and who manufactures the injection?
Answer: Not determinable from the provided inputs.
How does supplier identification typically work for peramivir injection?
Peramivir injectable supply chains are usually confirmed via:
- FDA product labeling “Manufactured for” / “Distributed by” statements
- FDA Orange Book listed drug product applicants and manufacturers
- DMF holder and API manufacturing sites for peramivir
- GMP inspection records tying sites to drug substance and drug product
No such label, Orange Book, NDA number, or DMF/site dossier details were provided.
Which peramivir manufacturers are listed on the FDA Orange Book?
Answer: Not determinable from the provided inputs.
What data points are required to map Orange Book “applicant” vs “manufacturer”?
Orange Book mapping depends on access to:
- Listed drug name, dosage form, strength
- Applicant and manufacturer names
- Submission type and patent list that anchors the NDA record
None of those identifiers are present here.
Who makes peramivir injection (IV) under contract manufacturing?
Answer: Not determinable from the provided inputs.
What contract manufacturing signals are typically used?
Drug product CMOs are identified by:
- “Manufactured by” statements on package inserts
- NDA labeler/manufacturer fields
- Procurement disclosures in litigation or settlement filings
No label or litigation record is included.
What is the peramivir supply chain for raw materials and intermediates?
Answer: Not determinable from the provided inputs.
Intermediates and critical reagents
Peramivir API manufacturing usually relies on intermediate and reagent availability, but without the specific manufacturing route or DMF, supplier identification cannot be stated accurately.
How many peramivir API suppliers exist globally?
Answer: Not determinable from the provided inputs.
Why a count requires dossier-level data
A reliable number requires:
- DMF holders and active site approvals
- Inspectable manufacturing sites
- Commercial batch traceability via labeling and regulatory filings
None of this is provided.
What generic or alternate-supplier risks exist for peramivir?
Answer: Not determinable from the provided inputs.
What would be evaluated in supplier risk
Supplier risk for injectables is assessed via:
- single-site dependency
- import geography constraints
- batch supply interruptions in FDA inspection outcomes
- quality system sanctions or recalls
No operational, inspection, or recall data is included.
Key Takeaways
- Peramivir supplier identification requires drug-specific regulatory and labeling identifiers (NDA/DMF, labeler/manufacturer, dosage form/strength, and listed sites).
- Those inputs are not provided, so supplier names, API CMOs, and drug product manufacturers cannot be stated without producing incomplete or inaccurate results.
FAQs
- How do I find who manufactures peramivir injection in the US?
- What Orange Book fields identify peramivir’s drug product manufacturer?
- How can I confirm peramivir API suppliers from DMF records?
- Which documents list peramivir manufacturer on US labeling (carton and insert)?
- What quality events (FDA inspections/recalls) affect peramivir supplier continuity?
References
No sources were provided or cited.
